Pluristem Therapeutics (PSTI) Preliminary COVID-19 Results a 'Game Changer' - H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Pluristem Therapeutics (PSTI) Adds to Recent Gains; Shares up 34%
April 9, 2020 9:31 AM EDTPluristem Therapeutics (NASDAQ: PSTI) adds to recent gains on its promising treatment for sick COVID-19 patients. Shares up 34%.
... MorePluristem Therapeutics (PSTI) Preliminary Data from COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure
April 7, 2020 7:51 AM EDTPluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today preliminary data from its compassionate use program, treating seven patients suffering from acute respiratory failure and inflammatory complications associated with COVID-19 with Pluristems PLX cells, in three medical centers in... More
